Dropping weight shouldn't be an uphill battle
Answer a few questions to help us understand your health concerns and medical history.
A licensed U.S. physician will review your account and determine eligibility to create a personalized treatment plan.
Once approved, our partner pharmacy will receive your prescription and ship your medication in as little as 3 days.
When you start your weight loss journey with us, you’ll also unlock in-depth guides that teach you how to self-administer your medication and scheduled check-ins after your first month of treatment.
If you need to adjust your dosage or experience side effects, our doctors can offer solutions within hours through your patient portal.
“What I liked about Remote Pharmacy is that the doctor doesn't just prescribe medication at their own will. They will ask how you feel.”
Verified Patient“I had a million and ten questions and Remote Pharmacy answered all of them in a timely manner.”
Verified Patient
GLP-1 medications target the brain's appetite-regulating centers, helping individuals eat less, especially after meals.
They slow down stomach emptying, providing a lasting feeling of fullness, reducing the urge to overeat.
Studies have demonstrated their effectiveness in helping people lose weight and maintain it for over a year.
Clinical trials found that people using GLP-1 medications lost an average of 15% of their body weight.1
Price varies by medication, with plans starting as low as $233/month.
Actual weight loss will vary per individual. Many GLP-1 patients can expect to lose 5% of their initial body weight but may lose up to 15% or more. Everyone is different and most success can be attributed to consistency, healthy habits, and dietary adjustments. Keep in mind that extreme weight loss is not a medically safe or desired effect. Healthy weight loss can be defined as losing 1 to 2 lbs per week.
Yes, GLP-1 medications are well-studied and effective treatments for weight loss. Specific precautions will be discussed with you by your Remote Pharmacy provider. The most common side effects of semaglutide may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Subcutaneous injections will be explained by your provider. Always consult
with your provider or licensed medical professional if you have any
questions.
You can also find our in-depth guide for preparing and injecting your
medication here:
https://remotepharmacy.com/instructions.php
Our Pharmacy Hub is located at 15600 NW 15th Ave, Miami, FL 33169. They can
be contacted at (305) 731 2318.
They maintain a license in 50 US states. Unfortunately, they cannot dispense
sterile compounds in the following U.S. states: LOUISIANA, MISSISSIPPI, and
NEW MEXICO.
Our partner pharmacy, GoGo Meds DBA Jungle Jims is located at 5484 Dixie
Highway, Fairfield, OH 45014. They can be contacted at (877) 858-3784. They maintain
a license in 44 US states.
Unfortunately, GoGo Meds DBA Jungle Jims cannot dispense sterile compounds
and do not have a license in the following U.S. states: CALIFORNIA,
DELAWARE, MASSACHUSETTS, MISSISSIPPI, NEVADA, NEW HAMPSHIRE, NEW JERSEY,
NORTH CAROLINA, TEXAS, and WEST VIRGINIA.
Our clinical providers are Beluga Health c/o Jonah Mink MD. Feel free to contact them at [email protected]. Beluga Health, P.A., a Florida professional corporation, has its office located at 1321 Upland Dr., Suite 18399, Houston, TX, 77043.
You can reach our customer support team through multiple channels:
1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. The Journal of clinical investigation, 101(3), 515–520. https://doi.org/10.1172/JCI990
3. Nauck, M. A., Meier, J. J., & Cavender, M. A. (2017). Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation, 136(9), 849-870. https://doi.org/10.1161/CIRCULATIONAHA.117.028136
4. Drucker D. J. (2016). The Cardiovascular Biology of Glucagon-like Peptide-1. Cell metabolism, 24(1), 15–30. https://doi.org/10.1016/j.cmet.2016.06.009
5. Creutzfeldt W. (1979). The incretin concept today. Diabetologia, 16(2), 75–85. https://doi.org/10.1007/BF01225454
